Physician profile
Debra A Grayson
NPI 1356333785
$3,261.80
in general payments reported to CMS, 2019-2025
34 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $292 · 2021: $633 · 2022: $637 · 2023: $527 · 2024: $513 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,275.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $377.36 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $159.45 | 2019-2024 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $129.30 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $124.64 | 2019-2023 | Segluromet, Steglujan, Belsomra |
| Aimmune Therapeutics, INC. | $103.05 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $100.38 | 2021-2023 | |
| Pfizer INC. | $99.61 | 2019-2025 | |
| Glaxosmithkline, LLC. | $95.53 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $86.01 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.83 | 2022-2025 | Xifaxan, Cycloset |
| Biohaven Pharmaceuticals, INC. | $68.04 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.45 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $50.31 | 2019-2023 | Seglentis |
| Lilly USA, LLC | $42.66 | 2021-2025 | Mounjaro, Zepbound |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.92 | 2020-2024 | Otezla, Repatha |
| Abbott Laboratories | $36.23 | 2021-2022 | |
| Almatica Pharma LLC | $34.67 | 2021-2024 | Loreev Xr, Teriparatide |
| Phathom Pharmaceuticals, INC. | $27.61 | 2023-2024 | Voquezna |
| Astellas Pharma US INC | $27.57 | 2022-2023 | Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $25.55 | 2022 | |
| Amarin Pharma, INC. | $24.88 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $24.43 | 2020 | |
| Allergan, INC. | $23.35 | 2020 | |
| Axsome Therapeutics, INC. | $22.74 | 2025 | Auvelity |
| Dexcom, INC. | $18.29 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $16.82 | 2022 | |
| Eisai INC. | $15.30 | 2021 | |
| Avvisto Therapeutics, LLC | $14.49 | 2024 | Cycloset |
| Supernus Pharmaceuticals, INC. | $13.59 | 2020 | |
| Ibsa Pharma INC. | $12.48 | 2021 | |
| Genentech USA, INC. | $11.92 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.69 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Grayson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.